Project Grant R01CA292653
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
The University of Pittsburgh received a $1,305,116 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to conduct a high-throughput screening campaign to identify allosteric inhibitors of the Bruton's Tyrosine Kinase (BTK) enzyme, which is associated with B-cell leukemias and lymphomas. The project, titled "Cell-Based HTS Campaign to Identify Negative Allosteric Modulators of the Leukemia-Associated Tyrosine Kinase, BTK", aims to develop novel...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $700,049 to the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. The award aims to study the impact of targeted tyrosine kinase inhibitor (TKI) therapies on cancer-related cognitive impairment (CRCI) among patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). The key products and services to be delivered under this 5-year...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Dr. Parikh at the Mayo Clinic to conduct clinical trials and develop new protocols for the treatment of chronic lymphocytic leukemia (CLL). Specifically, the $124,230 award will allow Dr. Parikh to: 1) complete two ongoing NCTN-sponsored clinical trials evaluating novel CLL treatments, including analyzing outcomes and biomarkers; and 2) develop the protocol and serve as...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $721,723 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding and overcoming Richter's Transformation, a complication of chronic lymphocytic leukemia. The key objectives are to determine the MGA/MYC/NME1 regulatory axis driving the transition from chronic lymphocytic leukemia to the more aggressive Richter's Transformation, and...
This federal Project Grant award for $499,902 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Rowan University aims to investigate the use of a novel MCL-1 inhibitor, KS18, to reverse acquired chemotherapeutic resistance in multiple myeloma (MM). The key objectives are to: 1) determine if inhibiting MCL-1 with KS18 can reverse chemotherapy resistance in MM cell lines, 2) evaluate whether MCL-1 inhibition can reverse bortezomib resistance in MM in vivo, and 3)...
This federal Project Grant award of $449,196 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Texas Southwestern Medical Center aimed at examining the mechanisms of resistance to tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC). The research focuses on understanding how TKI treatment triggers rapid sumoylation (a post-translational modification) of receptor tyrosine kinases (RTKs), transforming them...
This $4,753,460 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized Phase 2 clinical trial evaluating the PI3KD inhibitor roginolisib in combination with venetoclax and rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) patients. The study will be conducted by the Dana-Farber Cancer Institute, Inc. (DFCI), a prestigious non-profit cancer research center in Boston, Massachusetts....
This Project Grant award of $542,663 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research aimed at developing novel targeted therapies for acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The key objectives are to: Determine the preclinical efficacy of BRG1/BRM antagonists, including an inhibitor (FHD-286) and a degrader (AU15330), and assess their impact on the epigenome,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to investigate the role of an inhibitory receptor in regulating the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The $827,942 award, with a project period from July 2024 to June 2026, will enable the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to examine the causal effects of this inhibitory...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to understand the expression and function of monocyte/macrophage Fc gamma receptors with the goal of improving antibody-based therapies for chronic lymphocytic leukemia (CLL). The $621,637 award, effective September 1, 2024 through August 31, 2029, will fund three key research objectives: 1) Interrogate the mechanisms of influence of NOD2 stimulation on...